[New biological treatments for lung cancer]

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted therapies for non-small cell lung cancer (NSCLC) have emerged in the last five years.
• These therapies focus on cell signaling pathways controlling cell division and tumor angiogenesis.
• Significant advancements have been observed in specific patient subgroups.

Purpose of the Study:

• To review the efficacy of targeted therapies for non-small cell lung cancer (NSCLC).
• To discuss the role of epidermal growth factor receptor (EGFR) inhibitors and anti-angiogenesis agents.
• To explore future directions in multi-targeted drug development for cancer treatment.

Main Methods:

• Review of large clinical phase 2 and 3 trials involving EGFR tyrosine kinase receptor inhibitors.
• Analysis of data on bevacizumab (anti-VEGF monoclonal antibody) in combination with chemotherapy.
• Evaluation of diagnostic methods for identifying targetable mutations, such as EGFR tyrosine kinase domain mutations.

Main Results:

• EGFR inhibitors demonstrated efficacy in second and third-line settings for specific NSCLC patient populations (non-smokers, women, Asian patients), with response rates up to 40%.
• Bevacizumab combined with chemotherapy increased median survival to over 12 months in selected NSCLC patients (non-squamous, no cardiovascular history) with manageable toxicity.
• Molecular diagnostics, including FISH for EGFR gene amplification and mutation analysis, are crucial for patient selection.

Conclusions:

• Targeted therapies, particularly EGFR inhibitors and anti-angiogenesis agents, have significantly improved outcomes in selected NSCLC patients.
• Molecular profiling is essential for identifying patients likely to benefit from targeted treatments.
• Future cancer therapies are expected to involve multi-targeted drugs with combined anti-EGFR and anti-angiogenic properties.